Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Verve Therapeutics Inc increased its cash reserves by 75.45%, or 90.72m. Cash Flow from Financing totalled 212.58m or 1,807.94% of revenues. In addition the company used 149.55m for operations while cash from investing totalled 27.69m.
Cash flow per share | -2.37 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 6.01 |
---|---|
Tangible book value per share | 6.01 |
More ▼
Balance sheet in USDView more
Current ratio | 13.05 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼